knowledge -WSS

knowledge

author：fashion 2025-09-27 09:45:59 - browse：81566

Biogen announced a new round of cost cuts Tuesday, saying that it plans to save $700 million in operating costs and cut 1,000 jobs by 2025.

The company also released second quarter sales and earnings that handily topped the forecasts of Wall Street analysts. In early morning trading, Biogen shares rose more than 1%.

Biogen is attempting to recover from a series of corporate stumbles, the biggest of which involved the development and launch of the Alzheimer’s drug Aduhelm. The medicine was the first of a new class of disease-modifying Alzheimer’s drugs to be approved by the Food and Drug Administration. But doubts about the quality of the data behind the medicine meant that Medicare wouldn’t pay for it and doctors did not prescribe it. The resulting financial disaster cleaned out Biogen’s executive suite.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： In Spain, a hospital brews its own CAR

entertainment

WSS

Christmas in the PICU brings some surprising joy

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Grail spinoff by Illumina should end disastrous merger attempt

Intarcia’s device

HCA sued by state AG for quality issues at Mission Health

Grail spinoff by Illumina should end disastrous merger attempt

explore

knowledge

hotspot

Sports medicine is finally prioritizing gender equality

Three trends to watch in biotech in 2024

Medicare proposal to cover medical devices draws a mixed reaction

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Trump demands the U.S. pay no more for drugs than other countries … again

Hospitals owned by private equity see complications spike 25%

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Guidelines to prevent youth baseball injuries need more muscle

CommonSpirit Health keeps growing, even as it loses money

hotspot

Emergency workers more likely to restrain Black patients: study

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

How Vertex's cystic fibrosis drug is changing patients' lives

Ukraine and a new approach to mental health in war

Albert Bourla of Pfizer: worst biopharma CEO of 2023

focus

entertainment

hotspot

knowledge